Loncastuximab tesirine

Loncastuximab tesirine
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	CD19
Clinical data
Pronunciation	/ˌlɒnkæsˈtʌksɪmæb.ˈtɛsɪriːn/; LON-kas-TUK-si-mab TE-si-reen
Trade names	Zynlonta
Other names	ADCT-402, loncastuximab tesirine-lpyl
AHFS/Drugs.com	Monograph
MedlinePlus	a621031
License data	US DailyMed: Loncastuximab tesirine;
Routes of; administration	Intravenous
ATC code	L01FX22 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1879918-31-6;
DrugBank	DB16222;
ChemSpider	none;
UNII	7K5O7P6QIU;
KEGG	D11338;
Chemical and physical data
Formula	C6544H10048N1718O2064S52
Molar mass	147481.45 g·mol−1

Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma.^[2]^[3] It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.^[2]

The most common side effects include increased levels of gamma-glutamyltransferase (GGT, a liver enzyme), neutropenia (low levels of neutrophils, a type of white blood cell), tiredness, anemia (low levels of red blood cells), thrombocytopenia (low levels of blood platelets), nausea (feeling sick), peripheral edema (swelling due to fluid retention, especially of the ankles and feet) and rash.^[3]

Loncastuximab tesirine was approved for medical use in the United States in April 2021,^[2]^[4]^[5] and in the European Union in December 2022.^[3] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[6]

^ "Summary Basis of Decision for Zynlonta". Drug and Health Products Portal. 24 April 2025. Retrieved 10 July 2025.
^ ^a ^b ^c ^d "Zynlonta- loncastuximab tesirine injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 2 June 2021. Retrieved 1 June 2021.
^ ^a ^b ^c ^d Cite error: The named reference Zynlonta EPAR was invoked but never defined (see the help page).
^ "Drug Approval Package: Zynlonta". U.S. Food and Drug Administration (FDA). 24 May 2021. Archived from the original on 2 June 2021. Retrieved 1 June 2021.
^ "Drug Trials Snapshots: Zynlonta". U.S. Food and Drug Administration. 23 April 2021. Archived from the original on 28 July 2023. Retrieved 9 September 2023. This article incorporates text from this source, which is in the public domain.
^ Advancing Health Through Innovation: New Drug Therapy Approvals 2021. U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original (PDF) on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

[1] "Summary Basis of Decision for Zynlonta". Drug and Health Products Portal. 24 April 2025. Retrieved 10 July 2025.

[Zynlonta_FDA_label-2] "Zynlonta- loncastuximab tesirine injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 2 June 2021. Retrieved 1 June 2021.

[Zynlonta_EPAR-3] Cite error: The named reference Zynlonta EPAR was invoked but never defined (see the help page).

[4] "Drug Approval Package: Zynlonta". U.S. Food and Drug Administration (FDA). 24 May 2021. Archived from the original on 2 June 2021. Retrieved 1 June 2021.

[Zynlonta_FDA_snapshot-5] "Drug Trials Snapshots: Zynlonta". U.S. Food and Drug Administration. 23 April 2021. Archived from the original on 28 July 2023. Retrieved 9 September 2023. This article incorporates text from this source, which is in the public domain.

[New_Drug_Therapy_Approvals_2021-6] Advancing Health Through Innovation: New Drug Therapy Approvals 2021. U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original (PDF) on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

[1]

[2]

[3]

[4]

[5]

[6]